Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Justus-Liebig-Universität Gießen
- License Information
-
More Information
Article History
Received: 22 January 2025
Accepted: 14 March 2025
First Online: 21 April 2025
Declarations
:
: Not applicable.
: Not applicable.
: AM: received honoraria for lecturing and consulting from Alexion and Roche and travel reimbursements from Alexion. SP: received honoraria for lecturing and consulting from Sanofi-Avents, Merck Healthcare, Biogen, Novartis Pharma, Roche, Alexion and Hexal, travel reimbursements from Sanofi-Aventis, Merck Healthcare, Novartis Pharma, Roche, and Biogen, and research funding from DIAMED, Merck Healthcare, Novartis Pharma, Sanofi-Aventis and Biogen. SGM: received honoraria for lecturing, travel expenses and for attending meetings from Academy 2, Argenx, Alexion, Almirall, Amicus Therapeutics Germany, AstraZeneca, Bayer Health Care, Biogen, BioNtech, BMS, Celgene, Datamed, Demecan, Desitin, Diamed, Diaplan, DPmed, Gen Medicine and Healthcare products, Genzyme, Hexal AG, IGES, Impulze GmbH, Janssen Cilag, KW Medipoint, MedDay Pharmaceuticals, Medmile, Merck Serono, MICE, Mylan, Neuraxpharm, Neuropoint, Novartis, Novo Nordisk, ONO Pharma, Oxford PharmaGenesis, QuintilesIMS, Roche, Sanofi, STADA, Chugai Pharma, Teva, UCB, Viatris, Wings for Life international and Xcenda. He received research support from Alexion, Almirall, Amicus Therapeutics Germany, Argenx, Bayer Vital GmbH, BGP Products Operations (Viatris Company), Biogen, BMS, Demecan, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Hexal, Janssen, Merck Serono, Novartis, Novo Nordisk Pharma, ONO Pharma, Roche and Teva.
